- Beta Blockers
- Calcium Channel Blockers
- Sodium Channel Blockers
- Potassium Channel Blockers
- Others
Critical Care Antiarrhythmic Drugs Market size was valued at USD 825.1 million in 2023 and poised to grow at 6.3% CAGR from 2024-2030. The medications that belong to the family of drugs administered during emergency or intensive care for the treatment of irregular heart rhythms, or arrhythmias. These drugs form the cornerstone of management for life-threatening tachyarrhythmias, including ventricular tachycardia and atrial fibrillation, which may lead to serious complications if left untreated. The most common examples include amiodarone, lidocaine, and adenosine. The key drivers for this market are the growing incidence of cardiovascular diseases, particularly arrhythmias, which will continue to surge as the world population ages and lifestyle elements facilitate its growth. Demand for highly effective antiarrhythmic drugs translates to the critical healthcare setting, with lifestyle contributors such as poor diet, sedentary behaviour, and stress.
According to the American Heart Association, in 2016, cardiovascular diseases took more than 17.6 million lives and are estimated to take more than 23.6 million by the year 2030. However, many antiarrhythmic drugs are associated with significant side effects and potential toxicity, which can limit their use, especially in patients with multiple comorbidities. Whereas, ongoing clinical trials and new drug discoveries present opportunities for market expansion. Emerging markets, particularly in Asia-Pacific and Latin America, present significant growth opportunities due to increasing healthcare spending, improving healthcare infrastructure, and rising awareness of cardiovascular health. Expanding access to antiarrhythmic drugs in these regions could drive market growth.
Critical Care Antiarrhythmic Drugs Market Key Developments:
- In 2020: FDA approval of Sotalol IV for faster initiation of therapy in atrial fibrillation patients.
Critical Care Antiarrhythmic Drugs Market Summary
Study Period
2024-2030Base Year
2023CAGR
6.3%Largest Market
North AmericaFastest Growing Market
Asia PacificCritical Care Antiarrhythmic Drugs Market Dynamics
A major factor driving the market will be an increase in CVDs across the globe due to increasing incidents of conditions like arrhythmias, a result of aging populations, lifestyle, and comorbidities like hypertension and diabetes, among which begets the need for effective anti-arrhythmic drugs in critical care settings. It is most pronounced in countries with aging populations, such as North America and Europe, where CVDs are now the leading cause of morbidity and mortality. According to the World Heart Federation, in the past 30 years, the number of deaths from CVDs has increased by 60% worldwide from 12.1 million in 1990 to 20.5 million in 2021. An estimated 523 million people lived with some form of CVD in 2020, and approximately 19 million deaths were directly attributed to CVDs. This accounts for about 32% of all global deaths and an absolute increase of 18.7% compared with 2010.
North-America Got Significant Share
Critical Care Antiarrhythmic Drugs Market Regional Analysis
Based on the region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America dominates the market, it holds a huge share due to the high prevalence of cardiovascular diseases and well-developed infrastructure related to health care. A strong research and development culture is reported in the region, along with the easy availability of advanced medical technologies, making it led the critical care anti-arrhythmic drugs market. The high rate of FDA approvals for new drugs in the U.S. further strengthens the market in this region. According to the American Heart Association (AHA), cardiovascular diseases, including arrhythmias, are the leading cause of death in the United States, accounting for nearly 697,000 deaths in 2020. This high prevalence underscores the critical need for effective antiarrhythmic drugs in emergency settings. Followed by Europe and Asia Pacific, which is showing an upward trend due to rising spending on health, growing awareness about cardiovascular health, and access to advanced medical procedures.
Latin America
Europe
Asia Pacific
Middle East
North America
Critical Care Antiarrhythmic Drugs Market Segmentation
By Drug class
By Disease type
- Supraventricular Arrhythmias
- Ventricular Arrhythmias
- Others
By Distribution Channel
- Hospitals
- Clinics
- Ambulatory Centres
- Other
Geography
- North America
- Europe
- Asia pacific
- Latin America
- Middle east
Frequently Asked Questions
These are medications used to treat life-threatening arrhythmias in emergency and intensive care settings.
The rising prevalence of cardiovascular diseases, particularly arrhythmias, is a major driving factor.
North America is the leading region, driven by a high prevalence of cardiovascular diseases and advanced healthcare infrastructure.
Recent developments include the introduction of new drug formulations, FDA approvals, and the expansion of drug availability in emerging markets.
Challenges include regulatory hurdles, potential side effects of drugs, and competition from alternative therapies.
Key Features of the Report
- The critical care antiarrhythmic drugs market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
| 1.Executive Summary |
| 2.Global Critical Care Antiarrhythmic Drugs Market Introduction |
| 2.1.Global Critical Care Antiarrhythmic Drugs Market - Taxonomy |
| 2.2.Global Critical Care Antiarrhythmic Drugs Market - Definitions |
| 2.2.1.Drug class |
| 2.2.2.Disease type |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Critical Care Antiarrhythmic Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Critical Care Antiarrhythmic Drugs Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Critical Care Antiarrhythmic Drugs Market By Drug class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Beta Blockers |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Calcium Channel Blockers |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Sodium Channel Blockers |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Potassium Channel Blockers |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Critical Care Antiarrhythmic Drugs Market By Disease type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Supraventricular Arrhythmias |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Ventricular Arrhythmias |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Critical Care Antiarrhythmic Drugs Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Ambulatory Centres |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Other |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Critical Care Antiarrhythmic Drugs Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Critical Care Antiarrhythmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Beta Blockers |
| 9.1.2.Calcium Channel Blockers |
| 9.1.3.Sodium Channel Blockers |
| 9.1.4.Potassium Channel Blockers |
| 9.1.5.Others |
| 9.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Supraventricular Arrhythmias |
| 9.2.2.Ventricular Arrhythmias |
| 9.2.3.Others |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Clinics |
| 9.3.3.Ambulatory Centres |
| 9.3.4.Other |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Critical Care Antiarrhythmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Beta Blockers |
| 10.1.2.Calcium Channel Blockers |
| 10.1.3.Sodium Channel Blockers |
| 10.1.4.Potassium Channel Blockers |
| 10.1.5.Others |
| 10.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Supraventricular Arrhythmias |
| 10.2.2.Ventricular Arrhythmias |
| 10.2.3.Others |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Clinics |
| 10.3.3.Ambulatory Centres |
| 10.3.4.Other |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Critical Care Antiarrhythmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Beta Blockers |
| 11.1.2.Calcium Channel Blockers |
| 11.1.3.Sodium Channel Blockers |
| 11.1.4.Potassium Channel Blockers |
| 11.1.5.Others |
| 11.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Supraventricular Arrhythmias |
| 11.2.2.Ventricular Arrhythmias |
| 11.2.3.Others |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Clinics |
| 11.3.3.Ambulatory Centres |
| 11.3.4.Other |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Critical Care Antiarrhythmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Beta Blockers |
| 12.1.2.Calcium Channel Blockers |
| 12.1.3.Sodium Channel Blockers |
| 12.1.4.Potassium Channel Blockers |
| 12.1.5.Others |
| 12.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Supraventricular Arrhythmias |
| 12.2.2.Ventricular Arrhythmias |
| 12.2.3.Others |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Clinics |
| 12.3.3.Ambulatory Centres |
| 12.3.4.Other |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Critical Care Antiarrhythmic Drugs Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Beta Blockers |
| 13.1.2.Calcium Channel Blockers |
| 13.1.3.Sodium Channel Blockers |
| 13.1.4.Potassium Channel Blockers |
| 13.1.5.Others |
| 13.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Supraventricular Arrhythmias |
| 13.2.2.Ventricular Arrhythmias |
| 13.2.3.Others |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Clinics |
| 13.3.3.Ambulatory Centres |
| 13.3.4.Other |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Sanofi |
| 14.2.2.Mayne Pharma |
| 14.2.3.Baxter International Inc. |
| 14.2.4.Mylan N.V. |
| 14.2.5.Novartis AG. |
| 14.2.6.Pfizer Inc. |
| 14.2.7.Upsher-Smith Laboratories |
| 14.2.8.GlaxoSmithKline plc, |
| 14.2.9.Ammoed Pharma GmbH |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Sanofi
- Mayne Pharma
- Baxter International Inc.
- Mylan N.V.
- Novartis AG.
- Pfizer Inc.
- Upsher-Smith Laboratories
- GlaxoSmithKline plc,
- Ammoed Pharma GmbH